Hyperparathyroidism - Pipeline Insight, 2024

Hyperparathyroidism - Pipeline Insight, 2024

DelveInsight’s, “Hyperparathyroidism - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Hyperparathyroidism pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Hyperparathyroidism: Understanding

Hyperparathyroidism: Overview

Hyperparathyroidism is due to increased activity of the parathyroid glands, either from an intrinsic abnormal change altering excretion of parathyroid hormone (primary or tertiary hyperparathyroidism) or from an extrinsic abnormal change affecting calcium homoeostasis stimulating production of parathyroid hormone (secondary hyperparathyroidism).

The majority of primary hyperparathyroidism (PHPT) patients do not present with the classic symptoms of kidney stones or severe bone disease. Individuals are more often diagnosed today through routine biochemical laboratory testing done for other purposes. Most patients with PHPT have single adenomatous (80%) or multiply hyperplastic (15% to 20%) parathyroid tissue. Multiglandular disease can also be manifest as two and, very rarely, three adenomas. Parathyroid carcinoma is rare, accounting for <1% of all cases of PHPT (11). Suspicion for parathyroid cancer should be increased when patients, who are typically younger by about one decade, present with much higher serum calcium and PTH levels. Invariably, renal and skeletal involvement will be readily apparent.

""Hyperparathyroidism- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hyperparathyroidism pipeline landscape is provided which includes the disease overview and Hyperparathyroidism treatment guidelines. The assessment part of the report embraces, in depth Hyperparathyroidism commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence in Hyperparathyroidism R&D. The therapies under development are focused on novel approaches to treat/improve in Hyperparathyroidism.
• In June 2021, has received Marketing Authorization approval today for UPASITA® IV Injection Syringes (generic name: Upacicalcet Sodium Hydrate; ""UPASITA) for the treatment of secondary hyperparathyroidism in patients on hemodialysis.
• Amgen announced that the U.S. Food and Drug Administration (FDA) has approved Parsabiv™ (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. Parsabiv is the first therapy approved for this condition in 12 years and the only calcimimetic that can be administered intravenously by the dialysis health care team three times a week at the end of the hemodialysis session.

This segment of the Hyperparathyroidism report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hyperparathyroidism Emerging Drugs

• VS-105: Vidasym

VS-105, a novel vitamin D receptor agonist (VDRAs), is in clinical studies for the treatment of osteoporosis and hyperparathyroidism secondary to chronic kidney disease. In the completed SAD/MAD studies involving healthy subjects, VS-105 is well tolerated with no drug-related AEs or other issues. The China right of this program has been licensed out. The ex-China right is still available.

• MT-4580: Mitsubishi Tanabe Pharma

Evocalcet (MT-4580) is a novel oral calcimimetic compound that was developed by screening for the ability to activate CaR in vitro and by evaluating the emetic effect in vivo. The purpose of this study was to characterize the pharmacological profiles of evocalcet.

Further product details are provided in the report……..

Hyperparathyroidism: Therapeutic Assessment

This segment of the report provides insights about the different Hyperparathyroidism drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Hyperparathyroidism

There are approx. 5+ key companies which are developing the therapies for Hyperparathyroidism. The companies which have their Hyperparathyroidism drug candidates in the most advanced stage, i.e. Phase III include, Mitsubishi Tanabe Pharma.

• Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Hyperparathyroidism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Small Molecule
• Peptide
• Vitamin D analogues
• Molecule Type

Products have been categorized under various Molecule types such as

• Intravenous
• Oral
• Subcutaneous
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hyperparathyroidism: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hyperparathyroidism therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hyperparathyroidism drugs.

Hyperparathyroidism Report Insights

• Hyperparathyroidism Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hyperparathyroidism Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hyperparathyroidism drugs?
• How many Hyperparathyroidism drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hyperparathyroidism?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hyperparathyroidism therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hyperparathyroidism and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Vidasym Inc.
• Mitsubishi Tanabe Pharma
• Shanghai Hengrui Pharmaceutical

Key Products

• VS-105
• MT-4580
• SHR6508